Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2019 - 2021)

Protagonist Therapeutics' Amortization of Deferred Charges history spans 3 years, with the latest figure at $491000.0 for Q3 2021.

  • For Q3 2021, Amortization of Deferred Charges rose 10.59% year-over-year to $491000.0; the TTM value through Sep 2021 reached $1.8 million, up 2.59%, while the annual FY2020 figure was $1.8 million, 0.95% down from the prior year.
  • Amortization of Deferred Charges for Q3 2021 was $491000.0 at Protagonist Therapeutics, up from $443000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $491000.0 in Q3 2021 and bottomed at $443000.0 in Q2 2020.
  • The 3-year median for Amortization of Deferred Charges is $444000.0 (2019), against an average of $449545.5.
  • The largest annual shift saw Amortization of Deferred Charges decreased 3.27% in 2020 before it rose 10.59% in 2021.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $445000.0 in 2019, then decreased by 0.22% to $444000.0 in 2020, then rose by 10.59% to $491000.0 in 2021.
  • Per Business Quant, the three most recent readings for PTGX's Amortization of Deferred Charges are $491000.0 (Q3 2021), $443000.0 (Q2 2021), and $444000.0 (Q1 2021).